Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.
Individuals with Major Depressive Disorder (MDD) vary regarding the rate, magnitude and stability of symptom changes during antidepressant treatment. Growth mixture modeling (GMM) can be used to identify patterns of change in symptom severity over time. Quantitative electroencephalographic (QEEG) cordance within the first week of treatment has been associated with endpoint clinical outcomes but has not been examined in relation to patterns of symptom change. Ninety-four adults with MDD were randomized to eight weeks of double-blinded treatment with fluoxetine 20mg or venlafaxine 150mg (n=49) or placebo (n=45). An exploratory random effect GMM was applied to Hamilton Depression Rating Scale (Ham-D(17)) scores over 11 timepoints. Linear mixed models examined 48-h, and 1-week changes in QEEG midline-and-right-frontal (MRF) cordance for subjects in the GMM trajectory classes. Among medication subjects an estimated 62% of subjects were classified as responders, 21% as non-responders, and 17% as symptomatically volatile-i.e., showing a course of alternating improvement and worsening. MRF cordance showed a significant class-by-time interaction (F((2,41))=6.82, p=.003); as hypothesized, the responders showed a significantly greater 1-week decrease in cordance as compared to non-responders (mean difference=-.76, Std. Error=.34, df=73, p=.03) but not volatile subjects. Subjects with a volatile course of symptom change may merit special clinical consideration and, from a research perspective, may confound the interpretation of typical binary endpoint outcomes. Statistical methods such as GMM are needed to identify clinically relevant symptom response trajectories.
Hunter
Aimee M
AM
Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024-1759, United States. amhunter@ucla.edu
Muthén
Bengt O
BO
Cook
Ian A
IA
Leuchter
Andrew F
AF
D000928:Antidepressive Agents / Q000627:therapeutic use*; D001931:Brain Mapping; D003511:Cyclohexanols / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology*; D004311:Double-Blind Method; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D009716:Numerical Analysis, Computer-Assisted; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
D000928:Antidepressive Agents; D003511:Cyclohexanols; D005473:Fluoxetine; D000069470:Venlafaxine Hydrochloride